Susan Edelstein

Bio:

Susan Edelstein, Ph.D., is Senior Vice President of Clinical Research at Ardelyx, a biopharmaceutical company focused on developing first-in-class therapies for cardiorenal and gastrointestinal diseases, where she leads the company’s clinical development and clinical operations programs. She supported the development and subsequent approval of IBSRELA for IBS-C and XPHOZAH for dialysis patients with hyperphosphatemia. Dr. Edelstein has more than 25 years of experience in clinical research and drug development across multiple therapeutic areas and has played a key role in advancing Ardelyx’s clinical programs and regulatory submissions.

Dr. Edelstein joined Ardelyx in 2015 after serving as a consultant to the company for 4 years. Earlier in her career she held clinical research and development roles in several biotechnology companies. She completed a post-doctoral fellowship at the HNRC at Tufts University in the lab of Dr. Andrew Greenberg studying the molecular, metabolic, and hormonal regulation of obesity and insulin resistance associated with diabetes. She received her Ph.D. in Biochemistry from Boston University School of Medicine and earned her A.B. from Smith College.